STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner
- 1 August 2009
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 78 (3), 249-260
- https://doi.org/10.1016/j.bcp.2009.04.007
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsBlood, 2003
- Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitroMolecular Cancer, 2003
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaCancer Cell, 2002
- Tyrosine kinase oncogenes in normal hematopoiesis and hematological diseaseOncogene, 2002
- Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.2002
- Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.2002
- The role of mitogen-activated protein (MAP) kinase in breast cancerThe Journal of Steroid Biochemistry and Molecular Biology, 2002
- Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3Oncogene, 2000